Biosynth Acquires Cambridge Research Biochemicals

Biosynth—supplier of critical raw materials to the life sciences industry—has acquired Cambridge Research Biochemicals (CRB)—an independent producer of custom-made peptide and antibody tools. The acquisition was announced in a May 9, 2023 press release.

Through this acquisition, Biosynth will gain CRB’s expertise in complex peptide chemistry and fluorescent dye labeling, bolstering its peptide division, which has existing operations in the United States and the Netherlands. Additionally, CRB’s custom antibody capacity in Europe will provide further support to Biosynth’s customers through the generation of novel, complex, or unusual mono- and polyclonal antibodies that are not available in catalogs.

“CRB has a long history in the peptide and antibody field, and we are excited to welcome their highly skilled team to our growing peptide division,” said Urs Spitz, CEO and president of Biosynth, in the press release. “Having a network of peptide sites at key locations, staffed by industry experts, allows us to best serve our customers throughout research and development and with the most complex and labelled peptides and high-quality antibodies.”

“We are excited to be joining the Biosynth family,” added Emily Humphrys, managing director of CRB, in the press release. “As one of the longest established peptide companies, we have over 40 years of experience and are proud to have a strong track record for peptide and antibody excellence with our customers. We see great similarities in the approach that Biosynth already take in leading with science and customer focus.”

Source: Biosynth